Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

Mucosal Barrier of the Stomach

Mucosal Barrier of the Stomach

The gastric glands contain parietal cells that secrete hydrochloric acid (HCl) for digestion. The cells secrete HCl because it is highly corrosive and essential for breaking down food. To achieve this, they secrete hydrogen and chloride ions into the lumen of the gastric glands, which combine to form HCl.
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Development of a novel safety assessment method for quality control of mRNA vaccines based on lung biomarker gene expression.

Vaccine·2025

Same author

Calboxyvinyl polymer adjuvant enhances respiratory iga responses through mucosal and systemic administration.

NPJ vaccines·2025

Same author

Recombinant mycobacterial DNA-binding protein 1 with post-translational modifications boosts IFN-gamma production from BCG-vaccinated individuals' blood cells in combination with CpG-DNA.

Scientific reports·2024

Same author

Effect of cigarette smoke on mucosal vaccine response with activation of plasmacytoid dendritic cells: The outcomes of in vivo and in vitro experiments.

Vaccine·2023

Same author

Streptococcus pyogenes TrxSR Two-Component System Regulates Biofilm Production in Acidic Environments.

Infection and immunity·2021

Same author

Evaluation of a booster tuberculosis vaccine containing mycobacterial DNA-binding protein 1 and CpG oligodeoxynucleotide G9.1 using a Guinea pig model that elicits immunity to Bacillus Calmette-Guérin.

Tuberculosis (Edinburgh, Scotland)·2021

Search research articles

Related Experiment Video

Updated: Apr 16, 2026

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

CpG oligodeoxynucleotides as mucosal adjuvants.

Sumiko Iho¹, Jun-ichi Maeyama, Fumiko Suzuki

¹a Host Defense Laboratory; Faculty of Medical Sciences; University of Fukui ; Yoshida-gun , Fukui , Japan.

Human Vaccines & Immunotherapeutics

|March 10, 2015

Summary

CpG oligodeoxynucleotides, mimicking bacterial DNA, activate immune responses. Phosphodiester-linked versions show promise as safe mucosal adjuvants, enhancing vaccine efficacy at the vaccination site.

Keywords:

Ab, antibody BCG, Mycobacterium bovis Bacillus Calmette-Guerin CpG DT, diphtheria toxoid DTH, delayed-type hypersensitivity G, guanine IFN, interferon IgG1 IgG2a/c ODNs, oligodeoxynucleotides PBMCs, peripheral blood mononuclear cells PPD, purified protein derivative TLR, toll-like receptor Th1 mucosal adjuvant pDC pDCs, plasmacytoid dendritic cells palindrome phosphodiester phylaxis rCTB, recombinant cholera toxin B subunit sIgA, secretory IgA secretory IgA

More Related Videos

Author Spotlight: Development and Evaluation of a Cationic Nanoemulsion-Encapsulated Retinoic Acid System for Mucosal Vaccination

Author Spotlight: Development and Evaluation of a Cationic Nanoemulsion-Encapsulated Retinoic Acid System for Mucosal Vaccination

Published on: February 23, 2024

In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D

In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D

Published on: December 9, 2022

Related Experiment Videos

Last Updated: Apr 16, 2026

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

Author Spotlight: Development and Evaluation of a Cationic Nanoemulsion-Encapsulated Retinoic Acid System for Mucosal Vaccination

Author Spotlight: Development and Evaluation of a Cationic Nanoemulsion-Encapsulated Retinoic Acid System for Mucosal Vaccination

Published on: February 23, 2024

In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D

In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D

Published on: December 9, 2022

Area of Science:

Immunology
Vaccinology
Molecular Biology

Background:

Bacterial DNA with unmethylated CpG motifs activates plasmacytoid dendritic cells (pDCs) via toll-like receptor 9, inducing interferon-α and Th1 immune responses.
Synthetic CpG oligodeoxynucleotides (CpG ODNs) are developed for clinical use, often phosphorothioated for in vivo stability, but this can cause adverse effects.
Mucosal vaccines are gaining attention for inducing both mucosal and systemic immunity.

Purpose of the Study:

To review the discovery of CpG ODNs.
To explore the potential of phosphodiester-linked CpG ODNs as mucosal adjuvants.
To highlight the advantages of using CpG ODNs in mucosal vaccine development.

Main Methods:

Review of scientific literature on CpG ODNs and their interaction with toll-like receptor 9.
Analysis of the properties of phosphodiester-linked vs. phosphorothioated CpG ODNs.
Evaluation of the potential of CpG ODNs as adjuvants in mucosal vaccine strategies.

Main Results:

CpG ODNs are recognized by pDCs, stimulating immune responses.
Phosphodiester-linked CpG ODNs may offer a safer alternative to phosphorothioated versions for mucosal applications.
The presence of pDCs at mucosal sites makes CpG ODNs potentially effective local adjuvants.

Conclusions:

CpG ODNs represent a significant advancement in immune modulation.
Phosphodiester-linked CpG ODNs are promising candidates for mucosal adjuvants due to their targeted action and potentially lower adverse effects.
Further research into CpG ODNs could lead to improved mucosal vaccine formulations.